Effects of α-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 20 (4) , 321-325
- https://doi.org/10.1023/a:1024055522067
Abstract
We have recently shown that administration of α-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. The present experiments were designed to further explore PA involvement in breast cancer metastasis, using GFP-tagged MDA-MB-435 cells that can be tracked at the single cell level. Administration of DFMO significantly reduced the number of mice with pulmonary metastasis as well as the number of metastases per mouse. Both single-cell and multicellular metastatic deposits were similarly suppressed, thus suggesting that DFMO was inhibiting lung colonization by tumor cells rather than preventing progression of single-cell deposits to overt metastasis. DFMO administration also significantly reduced local recurrences following removal of the primary tumor. Prolongation of DFMO treatment to 14 weeks did not yield a superior antimetastatic effect beyond that provided by a 10-week course of therapy. Discontinuation of DFMO, on the other hand, was associated with local regrowth of the tumors and, possibly, recurrence of pulmonary metastasis. These data provide a rationale for testing the efficacy of anti-PA treatment within the context of adjuvant therapy of breast cancer.Keywords
This publication has 12 references indexed in Scilit:
- Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells.Clinical & Experimental Metastasis, 2002
- S-adenosylmethionine decarboxylase overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells.International Journal of Oncology, 2001
- Adjuvant systemic therapy for early breast cancer: progress and controversies.2001
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized TrialJNCI Journal of the National Cancer Institute, 2001
- Tamoxifen: Five Versus Ten Years--Is the End in Sight?JNCI Journal of the National Cancer Institute, 2001
- Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens.Breast Cancer Research and Treatment, 2001
- Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters.1999
- Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.1998
- Role of polyamines in the growth of hormone-responsive and - resistant human breast cancer cells in nude miceCancer Letters, 1992
- Role of polyamines in the growth of hormone-responsive experimental breast cancerin vivoBreast Cancer Research and Treatment, 1988